Cargando…

Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022

ABSTRACT: Interest in possible clinical uses for psychedelic drugs has grown steadily over the past decade. Although impressive findings from small studies stimulated considerable speculation and provided a strong justification for further study of psychedelic treatments, until very recently there w...

Descripción completa

Detalles Bibliográficos
Autor principal: Bogenschutz, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417937/
http://dx.doi.org/10.1192/j.eurpsy.2023.42
_version_ 1785088158276255744
author Bogenschutz, M.
author_facet Bogenschutz, M.
author_sort Bogenschutz, M.
collection PubMed
description ABSTRACT: Interest in possible clinical uses for psychedelic drugs has grown steadily over the past decade. Although impressive findings from small studies stimulated considerable speculation and provided a strong justification for further study of psychedelic treatments, until very recently there was a dearth of high-quality evidence for their efficacy, mechanisms of action, and appropriate treatment models for clinical use. However, during the past 2-3 years, there have been dramatic advances in the field. This presentation will focus on 5 publications in the field of psychedelic medicine that exemplify three important aspects of the recent progress in psychedelic research. (1) There has been a rapid increase in the number and size of controlled clinical trials of various psychedelic treatments. (2) Conceptual models for studying and potentially understanding the therapeutic effect of psychedelics have increased in sophistication and comprehensiveness. And (3) progress has been made toward developing models of treatment that would facilitate access to safe and effective psychedelic treatments, if and when they are approved by regulatory bodies. Although progress has been rapid, the field of psychedelic medicine is still in its infancy. Much more work on these and many other fronts will be necessary to discover what the study of psychedelics can contribute to healthcare and neuroscience. DISCLOSURE OF INTEREST: None Declared
format Online
Article
Text
id pubmed-10417937
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-104179372023-08-12 Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022 Bogenschutz, M. Eur Psychiatry Abstract ABSTRACT: Interest in possible clinical uses for psychedelic drugs has grown steadily over the past decade. Although impressive findings from small studies stimulated considerable speculation and provided a strong justification for further study of psychedelic treatments, until very recently there was a dearth of high-quality evidence for their efficacy, mechanisms of action, and appropriate treatment models for clinical use. However, during the past 2-3 years, there have been dramatic advances in the field. This presentation will focus on 5 publications in the field of psychedelic medicine that exemplify three important aspects of the recent progress in psychedelic research. (1) There has been a rapid increase in the number and size of controlled clinical trials of various psychedelic treatments. (2) Conceptual models for studying and potentially understanding the therapeutic effect of psychedelics have increased in sophistication and comprehensiveness. And (3) progress has been made toward developing models of treatment that would facilitate access to safe and effective psychedelic treatments, if and when they are approved by regulatory bodies. Although progress has been rapid, the field of psychedelic medicine is still in its infancy. Much more work on these and many other fronts will be necessary to discover what the study of psychedelics can contribute to healthcare and neuroscience. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10417937/ http://dx.doi.org/10.1192/j.eurpsy.2023.42 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Bogenschutz, M.
Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022
title Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022
title_full Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022
title_fullStr Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022
title_full_unstemmed Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022
title_short Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022
title_sort evidence that moved psychedelic medicine from the fringe to the mainstream in 2022
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417937/
http://dx.doi.org/10.1192/j.eurpsy.2023.42
work_keys_str_mv AT bogenschutzm evidencethatmovedpsychedelicmedicinefromthefringetothemainstreamin2022